News | Ultrasound Imaging | January 20, 2021

Exact Therapeutics Announces Innovative Probe Development Collaboration With GE Healthcare

January 20, 2021 — Exact Therapeutics, a clinical stage precision medicine company, announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT) across multiple disease conditions.

"We are delighted to collaborate with GE Healthcare, a leader in the field of diagnostic imaging and ultrasound. We look forward to working closely with GE Healthcare in developing an innovative ultrasound probe with the goal of enabling effective deployment of the ACT therapeutic amplification platform across indications for our forthcoming phase II clinical development program," said Rafiq Hasan, M.D., CEO of Exact Therapeutics AS.

ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.  ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London.

For more information: www.exact-tx.com

Related Content

Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

News | Cardio-oncology | February 25, 2021
February 25, 2020 — Results of a multi-centre, international, clinical trial co-led by Peter Munk Cardiac Centre (PMC
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
Dr Sahar Saleem placing the mummy in the CT scanner

Dr. Sahar Saleem placing the mummy in the CT scanner. Image courtesy of Sahar Saleem

News | Computed Tomography (CT) | February 22, 2021
February 22, 2021 — Modern medical technology is helping scholars tell a more nuanced story about the fate of an anci
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging